Suramin drug reduces emergence of drug resistance in mycobacteria: RGCB Study
The study tested the efficacy of Suramin, a WHO-approved drug used for treating sleeping sickness and river blindness infections. A family of harmful bacteria that causes diseases like TB and leprosy has become increasingly resistant to antibiotics, and the alarming situation warrants novel strategies to control evolution of drug resistance in mycobacteria, says a study by Dr. Krishna Kurthkoti, a scientist and researcher at Rajiv Gandhi Centre for Biotechnology (RGCB). The study, published in Antimicrobial agents and chemotherapy, reveals that application of antibiotics results in a two-phase killing of bacteria, with a significant part of the population being killed rapidly while a smaller sub-population of bacteria called ‘persister’ endures the antibiotic and persist in the environment for extended periods. The persisters also get killed because they remain susceptible to antibiotics, but the killing rate is much slower. Non-compliance with the duration of antibiotic therapy resul